Center for Cancer Nanotechnology Excellence and Translation (CCNE-T)

描述(由申请人提供)：这个癌症纳米技术卓越与翻译中心(CCNE-T)汇集了来自斯坦福大学、加州大学伯克利分校/劳伦斯·伯克利国家实验室、加州大学洛杉矶分校、南加州大学和麻省理工学院的科学家和医生。这笔赠款还利用了金丝雀基金会和弗雷德·哈钦森癌症中心在癌症生物标记物发现/验证方面的几项活动。这项研究提案围绕着我们的愿景，即体外诊断与体内诊断结合使用可以显著影响未来癌症患者的治疗。此外，我们认为，纳米技术可以通过蛋白质组纳米传感器进行体外诊断，也可以通过用于分子成像的纳米颗粒进行体内诊断。与癌症相关的生化通路的目标将是HER激酶轴，重点是预测和监测肺癌治疗的反应。另一个重点将是卵巢癌的早期检测。我们已经组建了一支高度跨学科的科学家团队，他们来自化学、材料科学和工程、分子成像、肿瘤学、癌症生物学、蛋白质工程和数学建模等领域，以实现我们的目标。我们高度利用斯坦福生物X和纳米科学与工程项目、加州纳米系统研究所以及斯坦福大学/UCL/VuSC/Fred Hutchinson癌症中心的资源。我们将利用我们创办的几家小公司和通用电气的大量资源。我们有直接链接到弗雷德·哈钦森卵巢孢子、最近资助的物理科学肿瘤学中心(PSOC)、ICMIC P50、ICBP和斯坦福大学的NTR。此外，金丝雀基金会将为临床试验提供300多万美元，以转化我们的纳米技术并帮助推广。提出了四个研究项目和三个核心。项目1侧重于新型智能纳米颗粒，包括拉曼和自组装纳米颗粒，项目2侧重于使用磁性纳米技术进行血液蛋白质组学和细胞分选。项目3的重点是使用多个纳米平台来询问单个循环中的肿瘤细胞。项目4的重点是使用光声学和拉曼纳米粒子对卵巢癌进行分子成像，并使用成像和磁纳米传感器监测治疗反应。Core#1将促进纳米信息学，Core#2将为纳米表征和纳米制造提供资源，Core#3将通过将我们的纳米技术与现有患者样本和正在进行的临床试验以及新的临床试验联系起来，促进临床翻译。随着我们高度互动和有凝聚力的计划专注于开发和验证用于抗癌治疗反应和早期癌症检测的纳米技术，我们将为癌症患者的利益设想、发明和创新。

DESCRIPTION (provided by applicant): This Center for Cancer Nanotechnology Excellence and Translation (CCNE-T) brings together scientists and physicians from Stanford University, University of California Berkeley/Lawrence Berkeley National Lab, University of California Los Angeles, University of Southern California and the Massachusetts Institute of Technology. The grant also leverages on several activities in cancer biomarker discovery/validation with the Canary Foundation and the Fred Hutchinson Cancer Center. This research proposal is centered around our vision that in vitro diagnostics used in conjunction with in vivo diagnostics can markedly impact future cancer patient management. Furthermore, we believe that nanotechnology can significantly advance both in vitro diagnostics through proteomic nanosensors and in vivo diagnostics through nanoparticles for molecular imaging. The cancer-related biochemical pathways targeted will be the Her kinase axis with a focus on predicting and monitoring response to lung cancer therapy. An additional focus will be on the earlier detection of Ovarian Cancer. We have assembled a highly interdisciplinary team of scientists from the fields of chemistry, materials science and engineering, molecular imaging, oncology, cancer biology, protein engineering, and mathematical modeling in order to accomplish our goals. We highly leverage resources at the Stanford Bio-X and Nanoscale Science and Engineering Programs, the California Nanosystems Institute, and the Cancer Centers of Stanford/UCL/VUSC/Fred Hutchinson. We will utilize significant resources at several small companies we have started and General Electric. We have direct links to a Fred Hutchinson Ovarian SPORE, a recently funded Physical Sciences Oncology Center (PSOC), the ICMIC P50, ICBP, and NTR at Stanford. Furthermore, the Canary Foundation will provide more than $3M towards clinical trials to translate our nanotechnologies and help with outreach. Four research projects and three cores are proposed. Project #1 focuses on novel smart nanoparticles including Raman and self-assembling nanoparticles, Project #2 focuses on the use of magneto-nanotechnology for blood proteomics and cell sorting. Project #3 focuses on the use of multiple nano-platforms to interrogate single circulating tumor cells. Project #4 focuses on molecular imaging of ovarian cancer with photoacoustics and Raman nanoparticles, and monitoring response to therapy using imaging and magneto-nanosensors. Core #1 will facilitate Nanoinformatics, Core #2 will provide resources for nanocharacterization and nanofabrication, Core #3 will facilitate clinical translation by linking our nanotechnologies to existing patient samples and ongoing as well as new clinical trials. With our highly interactive and cohesive program focused on developing and validating nanotechnology for anti-cancer therapy response and earlier cancer detection, we will imagine, invent, and innovate for the benefit of cancer patients.